Anti-Human GPVI Antibodies for Use in the Treatment of Cardiovascular Diseases
Summary
The European Patent Office published patent application EP3577136A1 for Acticor Biotech and collaborators, covering anti-human GPVI antibodies for treating cardiovascular diseases. The patent names Université Paris Cité, Université Paris XIII, INSERM, and Université Paris-Saclay as co-applicants. This grants intellectual property protection for the GPVI antibody technology across 32 designated EPO member states including all major European markets.
What changed
The European Patent Office published EP3577136A1, a patent application for anti-human GPVI antibodies developed by Acticor Biotech in collaboration with Université Paris Cité, Université Paris XIII, INSERM, and Université Paris-Saclay. The invention relates to the use of these antibodies in treating cardiovascular diseases. The patent claims priority to the C07K 16/28 and A61K 39/395 classifications and designates all major EPO member states including Germany, France, the United Kingdom, and Italy.
For biotechnology and pharmaceutical companies, this patent establishes intellectual property barriers in the GPVI-targeting cardiovascular treatment space within Europe. Acticor Biotech and its academic partners now hold exclusive rights to commercialize this antibody technology in designated territories, which may affect competitive positioning for similar cardiovascular therapies. Companies developing competing GPVI inhibitors or related thrombosis treatments should review this patent for potential freedom-to-operate implications.
What to do next
- Monitor for updates
Archived snapshot
Apr 8, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ANTI-HUMAN GPVI ANTIBODIES FOR USE IN THE TREATEMENT OF CARDIOVASCULAR DISEASES
Publication EP3577136A1 Kind: A1 Apr 01, 2026
Applicants
Acticor Biotech, Université Paris Cité, Université Paris XIII, INSERM (Institut National de la Santé
et de la Recherche Médicale), Université Paris-Saclay
Inventors
BILLIALD, Philippe, JANDROT-PERRUS, Martine, AVENARD, Gilles
IPC Classifications
C07K 16/28 20060101AFI20260122BHEP A61K 39/395 20060101ALI20260122BHEP A61K 39/00 20060101ALI20260122BHEP A61P 9/00 20060101ALI20260122BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for ChangeBridge: EPO Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Therapeutics (A61P) publishes new changes.